Stefan Buck

Dr. Stefan Buck is a Researcher at Erasmus MC, specializing in Internal Medicine with a focus on oncology and pharmacology. His work centers on prostate cancer treatments, drug interactions, and precision medicine. He completed his doctoral thesis in 2024, exploring taxane-based combination therapies for metastatic prostate cancer. His recent studies investigate pharmacokinetic interactions between drugs like darolutamide and docetaxel, as well as cabazitaxel-induced neutropenia risks. He collaborates widely, with research outputs published in journals like European Urology Oncology and Molecular Cancer Therapeutics.

Key research interests include drug efficacy optimization, side-effect mitigation in chemotherapy, and molecular mechanisms of antitumor therapies. His work bridges clinical pharmacology and translational medicine, aiming to improve patient outcomes through targeted approaches.